Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Aravive Inc (ARAV)

Aravive Inc (ARAV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up PR Newswire - Thu Dec 1, 2022

/PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this...

ONC.TO : 1.44 (+1.41%)
ONCY : 1.0400 (unch)
RHHBY : 40.7600 (+3.03%)
ARAV : 0.0401 (-13.39%)
CRBU : 2.49 (+2.05%)
KTRA : 0.2448 (+12.71%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up FinancialNewsMedia - Thu Dec 1, 2022

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –December 1, 2022 – USA News Group  –  A series of new Fast Track designations have been handed out by the United States...

ONCY : 1.0400 (unch)
ONC.TO : 1.44 (+1.41%)
RHHBY : 40.7600 (+3.03%)
ARAV : 0.0401 (-13.39%)
CRBU : 2.49 (+2.05%)
KTRA : 0.2448 (+12.71%)
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector BayStreet.ca - Thu Dec 1, 2022

USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy...

ONCY : 1.0400 (unch)
ONC.TO : 1.44 (+1.41%)
RHHBY : 40.7600 (+3.03%)
ARAV : 0.0401 (-13.39%)
CRBU : 2.49 (+2.05%)
KTRA : 0.2448 (+12.71%)
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates Globe Newswire - Thu Aug 11, 2022

Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b...

ARAV : 0.0401 (-13.39%)
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer Globe Newswire - Tue Jul 5, 2022

Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academia...

ARAV : 0.0401 (-13.39%)
Aravive Appoints Rudy Howard as Chief Financial Officer Globe Newswire - Fri Jun 3, 2022

HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted...

ARAV : 0.0401 (-13.39%)
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC) Globe Newswire - Thu May 26, 2022

Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022Development of biomarker offers the potential of a first in class...

ARAV : 0.0401 (-13.39%)
Aravive to Participate in H.C. Wainwright Global Investment Conference Globe Newswire - Tue May 17, 2022

HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat...

ARAV : 0.0401 (-13.39%)
Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting Globe Newswire - Fri Apr 29, 2022

HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to...

ARAV : 0.0401 (-13.39%)
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Globe Newswire - Fri Apr 1, 2022

HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to...

ARAV : 0.0401 (-13.39%)

Barchart Exclusives

Tesla Stock Forecast Post-Q2 Earnings: 'Present Imperfect, Future Uncertain' Barchart - 41 minutes ago
Tesla stock crashed following its Q2 earnings earlier this week. Here are the key takeaways from the report, and the forecast for the company amid a challenging macro environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot